Current clinical trials examining LuPSMA


“There's a hope that we can modulate PSMA expression with some drugs, increase the amount of PSMA on the tumors, [and] therefore increase the amount of radiation that we can target,” says Michael S. Hofman, MBBS (Hons), FRACP, FAANMS, FICIS.

In this video, Michael S. Hofman, MBBS (Hons), FRACP, FAANMS, FICIS, discusses the current clinical trials highlighted in the lecture, “LuPSMA: The Newest Treatment Class for Advanced Prostate Cancer,” presented recently at the 2021 Prostate Cancer Foundation Scientific Retreat. Hofman is a nuclear medicine physician and director of PROSTIC, Melbourne, Australia.

Related Videos
David I. Lee, MD, FACS, answers a question during a video interview
Todd M. Morgan, MD, answers a question during a Zoom video interview
Man talking with doctor | Image Credit: © rocketclips -
Prostate cancer cell division | Image Credit: © PRB ARTS -
Group of doctors reading a document | Image Credit: © Flamingo Images -
Blur image of hospital corridor | Image Credit: © zephyr_p -
Related Content
© 2024 MJH Life Sciences

All rights reserved.